Apnimed (NASDAQ:APMD) Stock Price Down 6.1% - Here's Why

Key Points

• Apnimed shares fell 6.1% to $20.32 in light trading, with volume down 97% from the stock’s average daily volume.
• Analyst sentiment remains positive: four analysts rate the stock Buy, one rates it Hold, and the consensus price target is $50.33 versus the recent share price.
• Apnimed reported quarterly EPS of $0.51 on $12.08 million in revenue, while major shareholder Morningside Venture Investment purchased 312,500 shares for $5 million.

Apnimed, Inc. (NASDAQ:APMD - Get Free Report) shares fell 6.1% on Monday. The company traded as low as $20.11 and last traded at $20.32. 15,898 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 483,218 shares. The stock had previously closed at $21.63.

Wall Street Analyst Weigh In

APMD has been the subject of a number of research analyst reports. Wall Street Zen upgraded Apnimed to a "hold" rating in a report on Saturday, August 8th. Lifesci Capital initiated coverage on Apnimed in a research report on Tuesday, August 25th. They set an "outperform" rating and a $50.00 price target for the company. Bank of America started coverage on Apnimed in a research note on Tuesday, August 25th. They set a "buy" rating and a $41.00 price target for the company. Cantor Fitzgerald started coverage on Apnimed in a report on Tuesday, August 25th. They issued an "overweight" rating and a $60.00 price objective on the stock. Finally, Evercore initiated coverage on Apnimed in a research note on Tuesday, August 25th. They issued an "outperform" rating on the stock. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, Apnimed currently has a consensus rating of "Moderate Buy" and an average price target of $50.33.

Apnimed Stock Up 0.2%

The firm's 50 day moving average price is $27.24.

Apnimed (NASDAQ:APMD - Get Free Report) last released its quarterly earnings results on Tuesday, September 8th. The company reported $0.51 EPS for the quarter. The company had revenue of $12.08 million for the quarter. Research analysts expect that Apnimed, Inc. will post -0.24 earnings per share for the current fiscal year.

Insider Activity at Apnimed

In other news, major shareholder Morningside Venture Investment bought 312,500 shares of the firm's stock in a transaction dated Monday, August 3rd. The stock was acquired at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the purchase, the insider owned 7,152,713 shares of the company's stock, valued at $114,443,408. This trade represents a 4.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Apnimed Company Profile

Apnimed Inc is a clinical-stage pharmaceutical company focused on developing oral medicines for sleep apnea. The company is working to provide pharmacologic alternatives to device-based treatments for patients with obstructive sleep apnea, a condition involving repeated interruptions in breathing during sleep.

Apnimed's lead candidate is AD109, an investigational once-daily combination of atomoxetine and aroxybutynine. The therapy is designed to improve the activity of muscles that help keep the upper airway open during sleep.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.